Back

Metabolic targeting with SGLT2 inhibitors differentially modulates cardiotoxicity and antitumor activity during HER2-targeted breast cancer therapy

20 June 2026 (13:15 - 14:15)
Organised by: Logo
Congress Presentation Part of: Research in cancer therapy-related cardiovascular toxicity: from bench to bedside Cardio-Oncology Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

8 More presentations in this session

Presentation thumbnail
SGLT2 inhibitor dapagliflozin attenuates pro-oxidative cardiomyocyte injury induced by PI3K selective inhibitor alpelisib and fulvestrant under hyperglycemia
Doctor N. Maurea (Naples, IT)
Abstract Slides
Presentation thumbnail
Transcriptome analysis of changes associated with dexrazoxane or GDF15 pretreatment to protect against doxorubicin in human embryonic stem cell-derived cardiomyocytes
Associate Professor E. Fung (Hong Kong, CN)
Abstract Slides
Presentation thumbnail
The prognostic value of global longitudinal strain in patients with AL amyloidosis with cardiac involvement treated with up-front daratumumab, cyclophosphamide, bortezomib and dexamethasone
Doctor J. Di Palma-Grisi (Hackensack, US)
Abstract Slides
Presentation thumbnail
Machine learning enhanced baseline risk prediction models for cancer therapy related cardiac dysfunction: a systematic review and critical appraisal of methodological quality
Doctor M. Andres (London, GB)
Abstract Slides
Presentation thumbnail
Performance of deep learning auto-segmentation models for cardiac substructures in paediatric proton beam therapy
Doctor K. Banfill (Manchester, GB)
Abstract Slides

Access the full session

Session thumbnail
Research in cancer therapy-related cardiovascular toxicity: from bench to bedside

The Event

Event poster

ESC Cardio-Oncology 2026

20 June 2026 13:15 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources